173 related articles for article (PubMed ID: 20354221)
1. Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system.
Ho PM; Tsai TT; Wang TY; Shetterly SM; Clarke CL; Go AS; Sedrakyan A; Rumsfeld JS; Peterson ED; Magid DJ
Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):303-8. PubMed ID: 20354221
[TBL] [Abstract][Full Text] [Related]
2. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care.
Ho PM; Tsai TT; Maddox TM; Powers JD; Carroll NM; Jackevicius C; Go AS; Margolis KL; DeFor TA; Rumsfeld JS; Magid DJ
Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):261-6. PubMed ID: 20407117
[TBL] [Abstract][Full Text] [Related]
3. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Ho PM; Peterson ED; Wang L; Magid DJ; Fihn SD; Larsen GC; Jesse RA; Rumsfeld JS
JAMA; 2008 Feb; 299(5):532-9. PubMed ID: 18252883
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention.
Sachdeva A; Bavisetty S; Beckham G; Shen AY; Aharonian V; Mansukhani P; Stone GW; Leon M; Moses J; Moore N; Hyett R; Contreras R; Brar SS
J Am Coll Cardiol; 2012 Dec; 60(23):2357-63. PubMed ID: 23141495
[TBL] [Abstract][Full Text] [Related]
6. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E
Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network.
Wiederkehr D; Berenson K; Casciano R; Stern L; Makenbaeva D; Mozaffari E; Lamerato L; Corbelli J
Curr Med Res Opin; 2009 Sep; 25(9):2317-25. PubMed ID: 19635042
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome.
Ho PM; Fihn SD; Wang L; Bryson CL; Lowy E; Maynard C; Magid DJ; Peterson ED; Jesse RL; Rumsfeld JS
Am Heart J; 2007 Nov; 154(5):846-51. PubMed ID: 17967588
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
Feldman DN; Fakorede F; Minutello RM; Bergman G; Moussa I; Wong SC
Am J Cardiol; 2010 Feb; 105(3):323-32. PubMed ID: 20102943
[TBL] [Abstract][Full Text] [Related]
10. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Bonello L; De Labriolle A; Lemesle G; Steinberg DH; Roy P; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2009 Jun; 73(7):866-70. PubMed ID: 19198009
[TBL] [Abstract][Full Text] [Related]
12. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
13. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population.
Wiederkehr D; Ogbonnaya A; Casciano R; Makenbaeva D; Mozaffari E; Corbelli J
Curr Med Res Opin; 2009 Sep; 25(9):2327-34. PubMed ID: 19635046
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
Brar SS; Kim J; Brar SK; Zadegan R; Ree M; Liu IL; Mansukhani P; Aharonian V; Hyett R; Shen AY
J Am Coll Cardiol; 2008 Jun; 51(23):2220-7. PubMed ID: 18534267
[TBL] [Abstract][Full Text] [Related]
17. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.
Berger JS; Frye CB; Harshaw Q; Edwards FH; Steinhubl SR; Becker RC
J Am Coll Cardiol; 2008 Nov; 52(21):1693-701. PubMed ID: 19007688
[TBL] [Abstract][Full Text] [Related]
18. Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US.
Stephenson JJ; Chang CL; Devecchis Wygant G; Hauch O; Cziraky MJ
Curr Med Res Opin; 2011 Jun; 27(6):1079-87. PubMed ID: 21438795
[TBL] [Abstract][Full Text] [Related]
19. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
